Stockscreener 앱 받기
95.40
3.49%
3.22
시장 영업 전:
95.73
0.33
+0.35%
전일 마감가:
$92.18
열려 있는:
$93.41
하루 거래량:
10.49M
Relative Volume:
0.82
시가총액:
$166.17B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
26.58
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
+2.32%
1개월 성능:
+9.69%
6개월 성능:
-23.18%
1년 성능:
-28.86%
1일 변동 폭
$91.91
$95.74
1주일 범위
$90.61
$95.74
52주 변동 폭
$81.97
$137.49
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
95.40 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
326.54 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.19 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.14 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
94.37 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Laboratories (NYSE: ABT) director receives 432 stock equivalent units as deferred fees - Stock Titan
Abbott Laboratories (ABT) director granted 416 stock equivalent units as board fees - Stock Titan
Abbott (ABT) director receives 363 stock equivalent units as board compensation - Stock Titan
Abbott (ABT) director Kevin Conroy receives 231 stock equivalent units as fees - Stock Titan
Form 4 Abbott Laboratories For: 1 July By Investing.com - Investing.com Canada
Abbott Laboratories (ABT) director receives 347 stock equivalent units as board compensation - Stock Titan
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Abbott (NYSE: ABT) EVP withholds 269 shares to satisfy tax obligations - Stock Titan
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott (ABT) Clears A Major Legal Risk As DOJ Ends Criminal Formula Probe - Yahoo Finance
Has Abbott Laboratories (ABT) Fallen Too Far Below Fair Value? - simplywall.st
Baird starts Abbott at Outperform, sees product pipeline driving growth - Yahoo Finance
Baird starts Abbott at Outperform, sees product pipeline driving growth By Investing.com - Investing.com Canada
Abbott Laboratories (ABT) Receives Outperform Rating from Baird with $121 Target - GuruFocus
Abbott Laboratories highlights diversified healthcare portfolio as a long-term driver - AD HOC NEWS
Abbott gains as Baird issues new outperform on growth outlook - MSN
Abbott stock gains as Baird issues new Outperform (ABT:NYSE) - Seeking Alpha
Baird initiates Abbott stock coverage with Outperform rating - Investing.com
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX, and More - Yahoo Finance
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
ABT Stock Quote Price and Forecast - CNN
US criminal probe into Abbott infant-formula plant closed - Global Food Industry News
Trump Admin Stopped Criminal Charges Against Abbott Nutrition for Infant Formula Illnesses - Food Safety Magazine
Abbott Laboratories earnings calendar, shares in focus on the NYSE - AD HOC NEWS
Abbott Laboratories was investigated for poisoning babies. After a $500,000 donation, Trump let them off the hook. - More Perfect Union | Substack
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo! Finance Canada
Form 4 Abbott Laboratories For: 29 June By Investing.com - Investing.com Canada
Abbott (ABT) EVP Cushman disposes 560 shares for tax withholding, retains 38,013 - Stock Titan
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Coca Cola Stock And 2 Defensive Picks For Steady Dividends - simplywall.st
MDL Sought for Abbott Spinal Cord Stimulator Lawsuits - AboutLawsuits.com
Price to sales forward of Abbott Laboratories Pakistan Limited – PSX:ABOT - TradingView
How Abbott's Largest Segment Is Preparing for the Next Growth Phase - TradingView
Abbott Laboratories dropped from Russell Top 50, shares hold above Tradegate level - AD HOC NEWS
Abbott Laboratories (ABT) Criminal Probe Closed by Justice Depar - GuruFocus
U.S. Justice Department Closes Criminal Probe into Abbott Laboratories - Intellectia AI
DOJ dropped Abbott baby formula criminal probe despite pile of evidence: WSJ (ABT:NYSE) - Seeking Alpha
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports - Reuters
Exclusive | The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case. - WSJ
In a Volatile Market, This Dividend Growth Stock Is Worth Every Penny of $1,000 - The Motley Fool
Enterprise value to revenue forward of Abbott Laboratories – NYSE:ABT - TradingView
Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market - Kavout | AI
Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about Children’s Growth - Insider Monkey
Brain Implants Market Size to Reach USD 18.39 Billion by 2035, Growing at 9.99% CAGR | SNS Insider - GlobeNewswire Inc.
Abbott Laboratories (ABT) Stock After Recent Rebound Is There Still Value Left - Yahoo Finance
Abbott Laboratories' Q2 2026 earnings: What to expect - MSN
Abbott (ABT) Expands In Europe With Instinct CGM And Emerging Market Medicines - simplywall.st
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now? - The Globe and Mail
Abbott Laboratories' Q2 2026 Earnings: What to Expect - Barchart.com
Enterprise value to EBIT forward of Abbott Laboratories – NYSE:ABT - TradingView
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.20%
자본화:
|
볼륨(24시간):